Additional Laboratory Testing for Chronic Spontaneous Urticaria
For chronic spontaneous urticaria (CSU), order the following basic laboratory tests: complete blood count with differential, C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR), total IgE, and IgG anti-thyroid peroxidase (anti-TPO) antibodies. 1
Core Laboratory Panel
The 2022 international urticaria guidelines establish these as the essential "basic tests" for all CSU patients:
- Complete blood count with differential - identifies basopenia and eosinopenia, which are markers of autoimmune CSU 1
- CRP or ESR - screens for inflammatory conditions and helps exclude differential diagnoses 1
- Total IgE level - distinguishes autoimmune from autoallergic CSU endotypes 1
- IgG anti-TPO antibodies - identifies autoimmune CSU and predicts treatment response 1
Rationale: Identifying CSU Endotypes
These tests serve a specific purpose beyond baseline monitoring. The ratio of IgG anti-TPO to total IgE is currently the best surrogate marker for autoimmune CSU 1. This distinction matters clinically:
Autoimmune CSU Pattern (Type IIb):
- Low or very low total IgE (<40 IU/mL)
- Elevated IgG anti-TPO (≥34 kU/L)
- Basopenia and/or eosinopenia on CBC
- Poor response to antihistamines (only 30% controlled) 2
- Poor response to omalizumab
- Better response to cyclosporine 3
Autoallergic CSU Pattern (Type I):
- High total IgE levels
- Normal or low IgG anti-TPO
- Better response to antihistamines (47% controlled) 2
- Good response to omalizumab 4, 3
Patients with both high anti-TPO (≥34 kU/L) AND low IgE (<40 IU/mL) have a 3.6-fold increased risk of having autoimmune CSU with positive basophil activation testing 2. This combination occurs in approximately 11% of CSU patients and identifies those who will likely need immunosuppressive therapy rather than omalizumab 2.
Additional Testing for Antihistamine-Refractory Cases
If patients fail to respond to H1-antihistamines, consider obtaining a CU Index (basophil histamine release assay or basophil activation test) to detect IgG autoantibodies against IgE or FcεRI 1. This test has an odds ratio of 4.5 for predicting refractory disease 5, though it is not widely available and omalizumab efficacy is independent of this result 1.
The autologous serum skin test can be performed but has limited clinical relevance since treatment decisions don't depend on it 1.
Before Starting Immunosuppressive Therapy
If cyclosporine is being considered (third-line therapy for omalizumab failures), monitor blood pressure and renal function (serum creatinine, BUN) at baseline and regularly during treatment 1. The guidelines specifically warn about risks of hypertension and renal failure with cyclosporine 1.
What NOT to Order
Avoid extensive screening panels. The guidelines explicitly moved away from broad autoimmune workups because they are low-yield and cost-ineffective 6. Additional testing should only be pursued if suggested by specific clinical findings, history, or physical examination 1.
Common Pitfall
Do not order ANA, comprehensive thyroid panels, or other autoimmune serologies routinely. While ANA positivity correlates with refractory disease (odds ratio 2.3) 5, it doesn't change management and the 2022 guidelines prioritize the more specific anti-TPO testing instead 1.